Clinical trials: Diabetes Type II
Type 2 Diabetes
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
The purpose of this study is to try and achieve similar glycemic control in general non-Intensive Care Unit (non-ICU) patients with Type 2 Diabetes with exenatide alone or in combination with basal insulin as compared to…
- Trial name
- NCT02455076
- Testing
- Exenatide, Glargine, Rapid-acting insulin analogs
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin.
- Trial name
- NCT01999218
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Glimerpiride
- Volunteers
- 1,326 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes.
- Trial name
- REALYSE (NCT05035082)
- Testing
- semaglutide, oral glucose-lowering medications (commercially available)
- Where
- 25 sites in United States
- Volunteers
- 1,018 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c) and body weight, and assessed the safety and…
- Trial name
- NCT01819272
- Testing
- Met DR, Met XR
- Volunteers
- 240 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
A study to assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3 days in Subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT02367066
- Testing
- AR-C165395XX
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)
A 2-period crossover study to assess the safety, tolerability and glucose-lowering effects of MK8245.
- Trial name
- NCT00790556
- Testing
- MK8245
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"
The purpose of this survey is to evaluate the long-term safety and efficacy of trelagliptin tablets in patients with type 2 diabetes mellitus in the routine clinical setting.
- Trial name
- NCT03555591
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 3,198 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition…
- Trial name
- NCT04531462
- Testing
- Empagliflozin
- Where
- 18 sites in Japan
- Volunteers
- 129 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with…
- Trial name
- ENGAGE-DM (NCT02910089)
- Testing
- Shared Decision Making
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Hypertension
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is…
- Trial name
- NCT00430040
- Testing
- Carvedilol Controlled Release (CR), lisinopril
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University at Buffalo
Diabetes
Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise
- Trial name
- NCT00316082
- Testing
- Saxagliptin, metformin
- Where
- 74 sites in United States, India and 2 more
- Volunteers
- 365 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01849289)
- Testing
- Insulin Degludec, Insulin Glargine
- Where
- 81 sites in United States, Brazil and 5 more
- Volunteers
- 833 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled…
- Trial name
- NCT02008682
- Testing
- liraglutide, sitagliptin
- Where
- 25 sites in China
- Volunteers
- 368 people
- Sponsor
- Novo Nordisk A/S
Hypoglycemia, Type 2 Diabetes
Hypoglycemia (Low Blood Sugar) and the Heart
The risk of hypoglycemia (low blood sugar) associated with the treatment of diabetes increases with age. Hypoglycemia is a common reason for admission to hospital for older patients with diabetes.
- Trial name
- NCT01980914
- Testing
- iPro2 glucose sensor attachment
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University of British Columbia
Type 2 Diabetes Mellitus, Hepatic Impairment
Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
This is a study to assess the pharmacokinetics and safety of ertugliflozin (MK-8835, PF-04971729) in participants with hepatic impairment versus healthy participants.
- Trial name
- NCT02115347
- Testing
- Ertugliflozin 15 mg
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Heart Diseases, Diabetes Mellitus, Type 2
Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness
This single-arm trial of the Cardiovascular Risk Reduction Among People Experiencing Homelessness (CV-Homes) intervention alone (n=8) will test the perception and feasibility of anticipated study procedures.
- Conditions
- Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension
- Trial name
- CV-Homes (NCT06025721)
- Testing
- Cardiovascular Risk Homeless Support
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Katherine Vickery
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine…
- Trial name
- SUSTAIN FORTE (NCT03989232)
- Testing
- Semaglutide
- Where
- 129 sites in United States, Bulgaria and 9 more
- Volunteers
- 961 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and < 11% will be enrolled into the wash-out phase or directly into the…
- Trial name
- NCT02157298
- Testing
- Dapagliflozin 5 mg
- Where
- 14 sites in Japan
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.